Daxor Corporation
Daxor Corporation DXR Peers
See (DXR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXR | $8.75 | -0.46% | 42.3M | -97.22 | -$0.09 | N/A |
| ISRG | $512.18 | -0.16% | 183.6B | 74.88 | $6.84 | N/A |
| BDX | $172.25 | -1.27% | 49.4B | 33.38 | $5.16 | +2.35% |
| BDXA | $59.24 | -2.24% | 49B | 21.44 | $2.76 | +2.35% |
| ALC | $86.19 | -3.29% | 42.6B | 38.31 | $2.25 | +0.39% |
| RMD | $249.46 | -1.09% | 36.6B | 27.81 | $8.97 | +0.85% |
| WST | $221.87 | -1.35% | 15.9B | 34.78 | $6.38 | +0.37% |
| BAX | $30.61 | -2.39% | 15.7B | -58.87 | -$0.52 | +2.61% |
| HOLX | $64.75 | -0.72% | 14.4B | 27.21 | $2.38 | N/A |
| COO | $69.70 | -1.66% | 13.9B | 33.67 | $2.07 | N/A |
Stock Comparison
DXR vs ISRG Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, ISRG has a market cap of 183.6B. Regarding current trading prices, DXR is priced at $8.75, while ISRG trades at $512.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas ISRG's P/E ratio is 74.88. In terms of profitability, DXR's ROE is +0.02%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, DXR is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs BDX Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, BDX has a market cap of 49.4B. Regarding current trading prices, DXR is priced at $8.75, while BDX trades at $172.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas BDX's P/E ratio is 33.38. In terms of profitability, DXR's ROE is +0.02%, compared to BDX's ROE of +0.06%. Regarding short-term risk, DXR is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs BDXA Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, BDXA has a market cap of 49B. Regarding current trading prices, DXR is priced at $8.75, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas BDXA's P/E ratio is 21.44. In terms of profitability, DXR's ROE is +0.02%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, DXR is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs ALC Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, ALC has a market cap of 42.6B. Regarding current trading prices, DXR is priced at $8.75, while ALC trades at $86.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas ALC's P/E ratio is 38.31. In terms of profitability, DXR's ROE is +0.02%, compared to ALC's ROE of +0.07%. Regarding short-term risk, DXR is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs RMD Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, RMD has a market cap of 36.6B. Regarding current trading prices, DXR is priced at $8.75, while RMD trades at $249.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas RMD's P/E ratio is 27.81. In terms of profitability, DXR's ROE is +0.02%, compared to RMD's ROE of +0.25%. Regarding short-term risk, DXR is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs WST Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, WST has a market cap of 15.9B. Regarding current trading prices, DXR is priced at $8.75, while WST trades at $221.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas WST's P/E ratio is 34.78. In terms of profitability, DXR's ROE is +0.02%, compared to WST's ROE of +0.17%. Regarding short-term risk, DXR is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs BAX Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, BAX has a market cap of 15.7B. Regarding current trading prices, DXR is priced at $8.75, while BAX trades at $30.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas BAX's P/E ratio is -58.87. In terms of profitability, DXR's ROE is +0.02%, compared to BAX's ROE of -0.08%. Regarding short-term risk, DXR is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs HOLX Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, HOLX has a market cap of 14.4B. Regarding current trading prices, DXR is priced at $8.75, while HOLX trades at $64.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas HOLX's P/E ratio is 27.21. In terms of profitability, DXR's ROE is +0.02%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, DXR is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs COO Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, COO has a market cap of 13.9B. Regarding current trading prices, DXR is priced at $8.75, while COO trades at $69.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas COO's P/E ratio is 33.67. In terms of profitability, DXR's ROE is +0.02%, compared to COO's ROE of +0.05%. Regarding short-term risk, DXR is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs BDXB Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, DXR is priced at $8.75, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas BDXB's P/E ratio is 7.60. In terms of profitability, DXR's ROE is +0.02%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, DXR is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs ATR Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, ATR has a market cap of 10B. Regarding current trading prices, DXR is priced at $8.75, while ATR trades at $151.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas ATR's P/E ratio is 27.63. In terms of profitability, DXR's ROE is +0.02%, compared to ATR's ROE of +0.15%. Regarding short-term risk, DXR is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs MASI Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, MASI has a market cap of 8.7B. Regarding current trading prices, DXR is priced at $8.75, while MASI trades at $161.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas MASI's P/E ratio is -29.47. In terms of profitability, DXR's ROE is +0.02%, compared to MASI's ROE of -0.41%. Regarding short-term risk, DXR is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs RGEN Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, RGEN has a market cap of 7.2B. Regarding current trading prices, DXR is priced at $8.75, while RGEN trades at $127.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas RGEN's P/E ratio is -303.62. In terms of profitability, DXR's ROE is +0.02%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, DXR is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs STVN Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, STVN has a market cap of 6.4B. Regarding current trading prices, DXR is priced at $8.75, while STVN trades at $23.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas STVN's P/E ratio is 44.30. In terms of profitability, DXR's ROE is +0.02%, compared to STVN's ROE of +0.09%. Regarding short-term risk, DXR is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs MMSI Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, MMSI has a market cap of 5.5B. Regarding current trading prices, DXR is priced at $8.75, while MMSI trades at $92.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas MMSI's P/E ratio is 45.35. In terms of profitability, DXR's ROE is +0.02%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, DXR is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs TFX Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, TFX has a market cap of 5.3B. Regarding current trading prices, DXR is priced at $8.75, while TFX trades at $119.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas TFX's P/E ratio is 37.14. In terms of profitability, DXR's ROE is +0.02%, compared to TFX's ROE of +0.03%. Regarding short-term risk, DXR is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs BLCO Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, BLCO has a market cap of 4.4B. Regarding current trading prices, DXR is priced at $8.75, while BLCO trades at $12.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas BLCO's P/E ratio is -12.09. In terms of profitability, DXR's ROE is +0.02%, compared to BLCO's ROE of -0.08%. Regarding short-term risk, DXR is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs HAE Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, HAE has a market cap of 3.4B. Regarding current trading prices, DXR is priced at $8.75, while HAE trades at $70.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas HAE's P/E ratio is 21.18. In terms of profitability, DXR's ROE is +0.02%, compared to HAE's ROE of +0.18%. Regarding short-term risk, DXR is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs ICUI Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, ICUI has a market cap of 3.2B. Regarding current trading prices, DXR is priced at $8.75, while ICUI trades at $132.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas ICUI's P/E ratio is -34.48. In terms of profitability, DXR's ROE is +0.02%, compared to ICUI's ROE of -0.05%. Regarding short-term risk, DXR is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs XRAY Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, XRAY has a market cap of 3.1B. Regarding current trading prices, DXR is priced at $8.75, while XRAY trades at $15.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas XRAY's P/E ratio is -3.50. In terms of profitability, DXR's ROE is +0.02%, compared to XRAY's ROE of -0.38%. Regarding short-term risk, DXR is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs WRBY Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, WRBY has a market cap of 2.7B. Regarding current trading prices, DXR is priced at $8.75, while WRBY trades at $22.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas WRBY's P/E ratio is -183.67. In terms of profitability, DXR's ROE is +0.02%, compared to WRBY's ROE of -0.04%. Regarding short-term risk, DXR is more volatile compared to WRBY. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs NVCR Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, DXR is priced at $8.75, while NVCR trades at $17.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas NVCR's P/E ratio is -10.71. In terms of profitability, DXR's ROE is +0.02%, compared to NVCR's ROE of -0.45%. Regarding short-term risk, DXR is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs QDEL Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, QDEL has a market cap of 2B. Regarding current trading prices, DXR is priced at $8.75, while QDEL trades at $28.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas QDEL's P/E ratio is -5.53. In terms of profitability, DXR's ROE is +0.02%, compared to QDEL's ROE of -0.11%. Regarding short-term risk, DXR is more volatile compared to QDEL. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs LMAT Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, DXR is priced at $8.75, while LMAT trades at $81.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas LMAT's P/E ratio is 41.12. In terms of profitability, DXR's ROE is +0.02%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs ATRC Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, ATRC has a market cap of 1.6B. Regarding current trading prices, DXR is priced at $8.75, while ATRC trades at $31.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas ATRC's P/E ratio is -39.04. In terms of profitability, DXR's ROE is +0.02%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, DXR is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs AZTA Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, AZTA has a market cap of 1.4B. Regarding current trading prices, DXR is priced at $8.75, while AZTA trades at $30.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas AZTA's P/E ratio is -9.36. In terms of profitability, DXR's ROE is +0.02%, compared to AZTA's ROE of -0.04%. Regarding short-term risk, DXR is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs PLSE Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, PLSE has a market cap of 1.1B. Regarding current trading prices, DXR is priced at $8.75, while PLSE trades at $15.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas PLSE's P/E ratio is -15.93. In terms of profitability, DXR's ROE is +0.02%, compared to PLSE's ROE of -0.71%. Regarding short-term risk, DXR is more volatile compared to PLSE. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs BLFS Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, BLFS has a market cap of 1B. Regarding current trading prices, DXR is priced at $8.75, while BLFS trades at $22.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas BLFS's P/E ratio is -115.95. In terms of profitability, DXR's ROE is +0.02%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, DXR is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs KMTS Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, KMTS has a market cap of 908.9M. Regarding current trading prices, DXR is priced at $8.75, while KMTS trades at $17.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas KMTS's P/E ratio is -9.22. In terms of profitability, DXR's ROE is +0.02%, compared to KMTS's ROE of +0.27%. Regarding short-term risk, DXR is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs STAA Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, STAA has a market cap of 845.9M. Regarding current trading prices, DXR is priced at $8.75, while STAA trades at $17.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas STAA's P/E ratio is -11.86. In terms of profitability, DXR's ROE is +0.02%, compared to STAA's ROE of -0.18%. Regarding short-term risk, DXR is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs ATRI Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, DXR is priced at $8.75, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas ATRI's P/E ratio is 64.50. In terms of profitability, DXR's ROE is +0.02%, compared to ATRI's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs ANGO Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, ANGO has a market cap of 432.1M. Regarding current trading prices, DXR is priced at $8.75, while ANGO trades at $10.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas ANGO's P/E ratio is -10.53. In terms of profitability, DXR's ROE is +0.02%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, DXR is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs NNNN Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, NNNN has a market cap of 380.1M. Regarding current trading prices, DXR is priced at $8.75, while NNNN trades at $8.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas NNNN's P/E ratio is 173.20. In terms of profitability, DXR's ROE is +0.02%, compared to NNNN's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to NNNN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs NYXH Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, NYXH has a market cap of 282.2M. Regarding current trading prices, DXR is priced at $8.75, while NYXH trades at $7.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas NYXH's P/E ratio is -3.31. In terms of profitability, DXR's ROE is +0.02%, compared to NYXH's ROE of -0.56%. Regarding short-term risk, DXR is more volatile compared to NYXH. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs SMTI Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, SMTI has a market cap of 256.1M. Regarding current trading prices, DXR is priced at $8.75, while SMTI trades at $28.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas SMTI's P/E ratio is -21.50. In terms of profitability, DXR's ROE is +0.02%, compared to SMTI's ROE of -0.29%. Regarding short-term risk, DXR is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs OSUR Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, OSUR has a market cap of 221M. Regarding current trading prices, DXR is priced at $8.75, while OSUR trades at $2.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas OSUR's P/E ratio is -7.04. In terms of profitability, DXR's ROE is +0.02%, compared to OSUR's ROE of -0.08%. Regarding short-term risk, DXR is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs STXS Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, STXS has a market cap of 183.2M. Regarding current trading prices, DXR is priced at $8.75, while STXS trades at $2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas STXS's P/E ratio is -6.87. In terms of profitability, DXR's ROE is +0.02%, compared to STXS's ROE of -2.17%. Regarding short-term risk, DXR is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs UTMD Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, UTMD has a market cap of 179.2M. Regarding current trading prices, DXR is priced at $8.75, while UTMD trades at $55.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas UTMD's P/E ratio is 14.55. In terms of profitability, DXR's ROE is +0.02%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, DXR is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs KRMD Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, KRMD has a market cap of 149M. Regarding current trading prices, DXR is priced at $8.75, while KRMD trades at $3.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas KRMD's P/E ratio is -26.92. In terms of profitability, DXR's ROE is +0.02%, compared to KRMD's ROE of -0.30%. Regarding short-term risk, DXR is more volatile compared to KRMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs ZTEK Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, ZTEK has a market cap of 147.1M. Regarding current trading prices, DXR is priced at $8.75, while ZTEK trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas ZTEK's P/E ratio is -17.62. In terms of profitability, DXR's ROE is +0.02%, compared to ZTEK's ROE of -0.58%. Regarding short-term risk, DXR is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs INFU Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, INFU has a market cap of 130.5M. Regarding current trading prices, DXR is priced at $8.75, while INFU trades at $6.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas INFU's P/E ratio is 41.47. In terms of profitability, DXR's ROE is +0.02%, compared to INFU's ROE of +0.08%. Regarding short-term risk, DXR is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs PDEX Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, PDEX has a market cap of 129M. Regarding current trading prices, DXR is priced at $8.75, while PDEX trades at $39.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas PDEX's P/E ratio is 14.33. In terms of profitability, DXR's ROE is +0.02%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, DXR is more volatile compared to PDEX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs ZJYL Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, ZJYL has a market cap of 106.5M. Regarding current trading prices, DXR is priced at $8.75, while ZJYL trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas ZJYL's P/E ratio is 34.00. In terms of profitability, DXR's ROE is +0.02%, compared to ZJYL's ROE of +0.13%. Regarding short-term risk, DXR is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs MBOT Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, MBOT has a market cap of 85.1M. Regarding current trading prices, DXR is priced at $8.75, while MBOT trades at $2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas MBOT's P/E ratio is -3.66. In terms of profitability, DXR's ROE is +0.02%, compared to MBOT's ROE of -0.85%. Regarding short-term risk, DXR is more volatile compared to MBOT. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs MLSS Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, MLSS has a market cap of 69.1M. Regarding current trading prices, DXR is priced at $8.75, while MLSS trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas MLSS's P/E ratio is -14.67. In terms of profitability, DXR's ROE is +0.02%, compared to MLSS's ROE of -0.83%. Regarding short-term risk, DXR is more volatile compared to MLSS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs AKYA Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, AKYA has a market cap of 61.3M. Regarding current trading prices, DXR is priced at $8.75, while AKYA trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas AKYA's P/E ratio is -1.28. In terms of profitability, DXR's ROE is +0.02%, compared to AKYA's ROE of -5.06%. Regarding short-term risk, DXR is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs OMIC Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, DXR is priced at $8.75, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas OMIC's P/E ratio is -0.58. In terms of profitability, DXR's ROE is +0.02%, compared to OMIC's ROE of -0.58%. Regarding short-term risk, DXR is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs IGAP Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, DXR is priced at $8.75, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas IGAP's P/E ratio is -10.52. In terms of profitability, DXR's ROE is +0.02%, compared to IGAP's ROE of +3.93%. Regarding short-term risk, DXR is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs NEPH Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, NEPH has a market cap of 39.4M. Regarding current trading prices, DXR is priced at $8.75, while NEPH trades at $3.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas NEPH's P/E ratio is 46.50. In terms of profitability, DXR's ROE is +0.02%, compared to NEPH's ROE of +0.09%. Regarding short-term risk, DXR is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs POCI Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, POCI has a market cap of 36.7M. Regarding current trading prices, DXR is priced at $8.75, while POCI trades at $4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas POCI's P/E ratio is -5.21. In terms of profitability, DXR's ROE is +0.02%, compared to POCI's ROE of -0.54%. Regarding short-term risk, DXR is more volatile compared to POCI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs SDC Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, DXR is priced at $8.75, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas SDC's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.02%, compared to SDC's ROE of -1.96%. Regarding short-term risk, DXR is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs NXGLW Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, NXGLW has a market cap of 28.4M. Regarding current trading prices, DXR is priced at $8.75, while NXGLW trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas NXGLW's P/E ratio is -0.22. In terms of profitability, DXR's ROE is +0.02%, compared to NXGLW's ROE of -0.63%. Regarding short-term risk, DXR is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs FEMY Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, FEMY has a market cap of 27.7M. Regarding current trading prices, DXR is priced at $8.75, while FEMY trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas FEMY's P/E ratio is -0.99. In terms of profitability, DXR's ROE is +0.02%, compared to FEMY's ROE of -3.92%. Regarding short-term risk, DXR is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs IVC Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, DXR is priced at $8.75, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas IVC's P/E ratio is -0.79. In terms of profitability, DXR's ROE is +0.02%, compared to IVC's ROE of -0.46%. Regarding short-term risk, DXR is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs HBIO Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, HBIO has a market cap of 22.5M. Regarding current trading prices, DXR is priced at $8.75, while HBIO trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas HBIO's P/E ratio is -0.39. In terms of profitability, DXR's ROE is +0.02%, compared to HBIO's ROE of -1.10%. Regarding short-term risk, DXR is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs RVP Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, RVP has a market cap of 20M. Regarding current trading prices, DXR is priced at $8.75, while RVP trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas RVP's P/E ratio is -0.88. In terms of profitability, DXR's ROE is +0.02%, compared to RVP's ROE of -0.27%. Regarding short-term risk, DXR is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs NXGL Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, NXGL has a market cap of 19.6M. Regarding current trading prices, DXR is priced at $8.75, while NXGL trades at $2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas NXGL's P/E ratio is -5.69. In terms of profitability, DXR's ROE is +0.02%, compared to NXGL's ROE of -0.63%. Regarding short-term risk, DXR is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs WOK Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, WOK has a market cap of 19.4M. Regarding current trading prices, DXR is priced at $8.75, while WOK trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas WOK's P/E ratio is -2.93. In terms of profitability, DXR's ROE is +0.02%, compared to WOK's ROE of -0.30%. Regarding short-term risk, DXR is more volatile compared to WOK. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs LUCYW Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, LUCYW has a market cap of 13.8M. Regarding current trading prices, DXR is priced at $8.75, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas LUCYW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.02%, compared to LUCYW's ROE of -0.95%. Regarding short-term risk, DXR is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs MHUA Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, MHUA has a market cap of 10.8M. Regarding current trading prices, DXR is priced at $8.75, while MHUA trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas MHUA's P/E ratio is 0.85. In terms of profitability, DXR's ROE is +0.02%, compared to MHUA's ROE of +0.09%. Regarding short-term risk, DXR is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs EKSO Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, EKSO has a market cap of 9.2M. Regarding current trading prices, DXR is priced at $8.75, while EKSO trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas EKSO's P/E ratio is -0.53. In terms of profitability, DXR's ROE is +0.02%, compared to EKSO's ROE of -0.82%. Regarding short-term risk, DXR is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs POAI Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, POAI has a market cap of 8.6M. Regarding current trading prices, DXR is priced at $8.75, while POAI trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas POAI's P/E ratio is -0.67. In terms of profitability, DXR's ROE is +0.02%, compared to POAI's ROE of -5.91%. Regarding short-term risk, DXR is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs LUCY Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, LUCY has a market cap of 7.6M. Regarding current trading prices, DXR is priced at $8.75, while LUCY trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas LUCY's P/E ratio is 0.05. In terms of profitability, DXR's ROE is +0.02%, compared to LUCY's ROE of -0.95%. Regarding short-term risk, DXR is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs STSS Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, STSS has a market cap of 5.6M. Regarding current trading prices, DXR is priced at $8.75, while STSS trades at $5.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas STSS's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.02%, compared to STSS's ROE of -0.99%. Regarding short-term risk, DXR is more volatile compared to STSS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs NSTG Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, DXR is priced at $8.75, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas NSTG's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.02%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, DXR is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs GCTK Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, GCTK has a market cap of 2.7M. Regarding current trading prices, DXR is priced at $8.75, while GCTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas GCTK's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.02%, compared to GCTK's ROE of +3.93%. Regarding short-term risk, DXR is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs GMVD Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $8.75, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas GMVD's P/E ratio is -0.01. In terms of profitability, DXR's ROE is +0.02%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs GMVDW Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $8.75, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas GMVDW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.02%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs AVGR Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, DXR is priced at $8.75, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas AVGR's P/E ratio is -0.05. In terms of profitability, DXR's ROE is +0.02%, compared to AVGR's ROE of -54.25%. Regarding short-term risk, DXR is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.
DXR vs APR Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, APR has a market cap of 0. Regarding current trading prices, DXR is priced at $8.75, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas APR's P/E ratio is 22.59. In terms of profitability, DXR's ROE is +0.02%, compared to APR's ROE of +9.81%. Regarding short-term risk, DXR is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs LMNX Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, LMNX has a market cap of 0. Regarding current trading prices, DXR is priced at $8.75, while LMNX trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas LMNX's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.02%, compared to LMNX's ROE of +0.03%. Regarding short-term risk, DXR is more volatile compared to LMNX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs ATRS Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, DXR is priced at $8.75, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas ATRS's P/E ratio is 14.95. In terms of profitability, DXR's ROE is +0.02%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, DXR is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs HRC Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, HRC has a market cap of 0. Regarding current trading prices, DXR is priced at $8.75, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas HRC's P/E ratio is 41.92. In terms of profitability, DXR's ROE is +0.02%, compared to HRC's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.
DXR vs IIN Comparison
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 42.3M. In comparison, IIN has a market cap of 0. Regarding current trading prices, DXR is priced at $8.75, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of -97.22, whereas IIN's P/E ratio is 226.45. In terms of profitability, DXR's ROE is +0.02%, compared to IIN's ROE of -0.00%. Regarding short-term risk, DXR is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.